



IYC 2011
International Year of
CHEMISTRY

ChemComm

This article is part of the
Supramolecular Chemistry web-
based thematic issue

celebrating the International Year of Chemistry 2011

Guest editors: Professors Philip Gale,
Jonathan Sessler and Jonathan Steed

All articles in this issue will be gathered together online at
www.rsc.org/chemcomm/supra.



Cite this: *Chem. Commun.*, 2011, **47**, 6126–6128

www.rsc.org/chemcomm

Combining carbohydrate substitutions at bioinspired positions with multivalent presentation towards optimising lectin inhibitors: case study with calixarenes†‡

Sabine André,^{§a} Cyrille Grandjean,^{§b} François-Moana Gautier,^b Silvia Bernardi,^c Francesco Sansone,^c Hans-Joachim Gabius^a and Rocco Ungaro^{*c}

Received 26th February 2011, Accepted 31st March 2011

DOI: 10.1039/c1cc11163a

Carbohydrate derivatisation and glycocluster formation are both known to enhance avidity for lectin binding. Using a plant toxin and human adhesion/growth-regulatory lectins (inter- and intrafamily comparisons) the effect of their combination is examined. In detail, aromatic substituents were introduced at the 2-*N* or 3'-positions of *N*-acetylglucosamine and the products conjugated to two types of calix[*n*]arenes (*n* = 4, 6) via thiourea-linker chemistry.

The growing realisation of the high-density coding capacity of glycans gives reason to devise routes for medical applications.¹ Thus, sugar receptors (lectins), which translate the carbohydrate-encoded message into cellular responses,^{1,2} become targets for drug development. Custom-made inhibitors would protect cells from harmful lectin activities.³ This concept can be turned into compounds by teaming up carbohydrate and supramolecular chemistry as follows: (i) tailoring the carbohydrate for best-possible contact complementarity to the lectin and (ii) acquiring lectin-matching multivalent presentation using suitable conjugation chemistry and scaffold selection. This perspective defines the aim of our study, *i.e.* to determine the effects of exploiting changes in a core unit together with clustered presentation. We used members of the family of human adhesion/growth-regulatory galectins² and a potent plant toxin akin to ricin (*Viscum album* agglutinin, VAA) as models.

Galectins share affinity to *N*-acetylglucosamine (LacNAc) but exhibit differing degrees of reactivity for the histo-blood group A epitope with its 3'-extension.⁴ Analyses by crystallography and flexible docking provided a detailed structural rationalization for this preference in the case of human galectin-3 and prompted synthetic work to capitalize on it.⁵ However, cross-reactivity of such derivatives between the chimera-type galectin-3 and at least the tandem-repeat-type galectins-4 and -9 was delineated. In addition to this bioinspired site for exchange of a hexopyranose by an aromatic moiety the 2-*N*-position of LacNAc, held in its place by three hydrogen bonds with the 3-hydroxyl group,^{5a,c} is a target. Aromatic substitution at this point has attracted interest as source for affinity generation.⁶ Due to its impact on solubility aromatic bisubstitution is impeded, as is introduction of bulky substituents.

In contrast to galectins, the plant toxin is less permissive for substitutions at these sites, therefore furnishing an inherent negative control.^{5b,7} Having on this ground reached the decision on where to enter structural additions, the previously proven compatibility of the linker chemistry with lectin activity could be applied.⁸ We selected the *cone* calix[4]arene and the conformationally mobile calix[6]arene as scaffolds to obtain clusters **1–4** (for structures, please see Scheme 1) owing to their graded activity profiles to galectins-1, -3 and -4 [with IC₅₀-values (inhibitor concentration to reach 50%-level of signal reduction) of lactoside clusters of 10 mM/0.6 mM for galectin-1, 0.2 mM/0.4 mM for galectin-3, 20 μM/5 μM for galectin-4].⁸ By testing the toxin and five human galectins against the free LacNAc derivatives and the glycoclusters in two assays of increasing biorelevance the following question is answered: will combination of ligand substitution with valency improve target properties?

A modified Danishefsky's iodosulfonamidation/azidation process,⁹ accompanied or not by a tin-mediated, regioselective arylation carried out on *D*-lactal derivatives, led to the key 1-azido-2-sulfonamido intermediates **5** and **6**, as precursors of 2-amido-1-isothiocyanato lactopyranoses (Scheme 2, see ESI for full details†). Acylation, removal of the sulfonamide protecting groups followed by selective reduction of the azides produced amines **7** and **8**, which were not isolated, but turned into the corresponding isothiocyanates **9** and **10**, or trapped

^a Institut für Physiologische Chemie, Tierärztliche Fakultät, Ludwig-Maximilians-Universität, Veterinärstr. 13, 80539 München, Germany. E-mail: gabius@tiph.vetmed.uni-muenchen.de; Fax: +49-89-2108-2508; Tel: +49-89-2108-2290


^b Laboratoire des Glucides, UMR CNRS 6219, Institut de Chimie de Picardie, Université de Picardie Jules Verne, 33 rue Saint-Leu, F-80039 Amiens, France. E-mail: cyrille.grandjean@u-picardie.fr; Fax: +33 322827560; Tel: +33 322828812

^c Dipartimento di Chimica Organica e Industriale, Università degli Studi, Parco Area delle Scienze 17/A, 43124 Parma, Italy. E-mail: rocco.ungaro@unipr.it; Fax: +39 0521 905472; Tel: +39 0521 905458


† This article is part of a ChemComm 'Supramolecular Chemistry' web-based themed issue marking the International Year of Chemistry 2011.

‡ Electronic supplementary information (ESI) available: Experimental procedures and compounds characterization. See DOI: 10.1039/c1cc11163a

§ Contributed equally.



Scheme 1 Structures of the calixarene glycoclusters based on 2/3'-substitutions in the LacNAc core.



Scheme 2 Preparation of isothiocyanates and reference ligands. *Reagents and conditions:* (i) thiophosgene (2 equiv.), CaCO_3 (3 equiv.), THF, 0 °C to r.t., overnight or 1,1'-thiocarbonyldiimidazole (1.5 equiv.), CH_2Cl_2 , r.t., 6 h; (ii) Ac_2O (3 equiv.), Et_3N (2 equiv.), CH_2Cl_2 , 0 °C to r.t., 2 h; (iii) MeONa , MeOH , r.t., 2 h.

with excess acetic anhydride and deprotected under Zemplén conditions to provide monovalent reference compounds **11** and **12**. Isothiocyanates **9** and **10** were then conjugated at the upper rim of amino-alkoxycalix[4/6]arenes followed by deprotection,⁸ to yield the glycoclusters **1–4** (Scheme 1). These glycoclusters, along with the monovalent controls, established the test panel. Physiologically, lectin functionality rests on binding to multivalent cellular glycoconjugates so that a matrix of a glycoprotein (here asialofetuin with up to nine terminal LacNAc units reactive with these lectins¹⁰) is an adequate model for testing.⁸ It served as reactant for the labelled lectins, and the inhibitory capacity of the compounds was determined by co-incubation of increasing amounts with the lectin in solution, as described in detail previously.⁸

As exemplarily shown for galectin-3 (Fig. 1 in ESI†), titrations revealed successively increasing extent of inhibition. They enabled the determination of IC_{50} -values. Used as control with predictive value, the tested substitutions were not favorable for VAA, as expected, although especially hexavalent presentation was still capable to establish some activity (Table 1). On the other hand, the inhibitory capacity was markedly increased by both types of substitution for galectin-3 (Fig. 1 in ESI†) and also galectin-9, less for galectin-4 (Table 1). The chimera-type galectin-3 maintained its characteristic sensitivity for *cone*-type tetravalent presentation (Table 1),

Table 1 IC_{50} -values of the free sugar derivatives and the sugar-bearing calix[4/6]arenes on binding for lectins to the glycoprotein^a

Type of inhibitor	VAA (0.5 $\mu\text{g ml}^{-1}$)	Galectin-3 (3 $\mu\text{g ml}^{-1}$)	Galectin-4 (5 $\mu\text{g ml}^{-1}$)	Galectin-9 (10 $\mu\text{g ml}^{-1}$)
Lactose	300	2500	1200	3000
11	4800	250	800	900
12	800	360	1250	300
1	2800	0.15	2.2	2.8
2	420	0.4	0.8	1.4
3	200	1.3	2.5	2.0
4	45	1.5	1.2	0.8

^a Coating with constant amount of 0.5 μg asialofetuin per well; assays to determine the IC_{50} -value given in μM sugar (please see Fig. 1 in ESI for example†) were routinely performed in triplicates for up to five independent series with standard deviations not exceeding 14.2%; for structures of the glycoclusters, please see Scheme 1.




Fig. 1 Inhibition of lectin binding to cells by the test compounds: the background control given as gray area, 100% -value as solid black line; data on percentage of positive cells/mean fluorescence intensity; data in each panel in the order of compound listing from bottom to top. (a, b) Galectin-4 (20 $\mu\text{g ml}^{-1}$) in the presence of 0.5 mM **12**, 10 μM **3** and 10 μM **4** (a), 0.5 mM **11**, 10 μM **1** and 10 μM **2** (b) for tumor-suppressor p16^{INK4a}-expressing pancreatic carcinoma Capan-1 cells. Assays were routinely performed in duplicates with up to five independent series on aliquots of cell suspensions of the same or next passage with standard deviations not exceeding 13.7%.

noted previously.⁸ An about 10-fold increase in inhibition ensued from 3'-substitution relative to lactose, and tetravalency lowered the IC_{50} -value to 0.15 μM (in sugar), relative to 200 μM reached for lactose-bearing *cone*-4-type calixarene.⁸ Both synthetic processes thus substantially add up to a significant gain in lectin-blocking capacity.

Whether the level of intrafamily selectivity is increased is answered by assays using galectins-1 and -8. Parallel testing disclosed rather weak inhibitory activity of the test panel with IC_{50} -values at least above 2 mM (not shown).

These results thus encouraged to proceed to examine these compounds in an *in vitro* system, *i.e.* challenging them with the task to protect cells from lectin binding. Cell surface glycans present a wide array of terminal galactosides along with particular spatial arrangements such as microdomains.

A recent study on galectins had proven their significance to form high-affinity contact sites for galectins-1 and -3.¹¹ Routinely, sugar-dependent lectin binding was ascertained and working concentrations for lectins in the linear range of signal intensity were set for comparative analysis, as described for initial calixarene testing previously.⁸

To interpret the scans presented in Fig. 1 (and Fig. 2 in ESI†) the binding of a labelled lectin to cells will shift the signal from the position of the control curve (in gray) to the right. An inhibitor will then interfere with lectin association (measured in percentage of positive cells and mean fluorescence intensity), moving the fluorescence profile back into the direction of the control. This principle can now readily be applied to the scans. In full accord with Table 1, the monovalent derivative **12** was not inhibitory at this tested concentration on VAA, whereas lactose and the two glyco-clusters **3** and **4** reduced lectin binding with increasing potency (Fig. 2a in ESI†). As noted previously,⁸ the *cone-4*-type presentation showed increased reactivity relative to the hexavalent compound in this system. This was further underscored by testing a different cell line, *i.e.* Chinese hamster ovary (CHO) cells with defective α 2,3-sialylation (Lec2 mutant¹²) (not shown). The tetravalent glycocluster **1** proved most active against galectin-3 (Fig. 2b in ESI†). In addition to the colon carcinoma cells, CHO cells with normal and reduced levels of α 2,3-sialylation and decreased β 1,6-branching of *N*-glycans (wild-type cells; Lec2/Lec4 mutant cells¹²) as well as pancreatic carcinoma cells, in which galectin-3 can act as competitive inhibitor against galectin-1 which induces anoikis under the control of the tumor suppressor p16^{INK4a},¹³ were processed, yielding comparable results. These data provide further evidence for the *cone-4*-type calixarene as suitable scaffold to hit galectin-3, irrespective of changes in the glycomic profile. Of note, galectin-1 binding was not affected at 10 μ M sugar concentration by this calixarene (not shown), and galectin-4 remained more sensitive to the hexa- than the tetravalent glycoclusters (Fig. 1). The same tendency with rather similar quantitative data was observed for galectin-9, with optimal activity for the 2-*N*-substituted hexavalent **4** (not shown), in full accord with the data from the solid-phase assays (Table 1).

Overall, our results illustrate the benefit to combine core derivatisation with conjugation of the biomimetic product to distinct scaffolds for multivalent display. Practically, the documented interference of galectin-3 with the pro-anoikis effector of galectin-1 as *e.g.* in pancreatic cancer *in vitro*,¹³ can be precluded by using such a selective blocking reagent, *i.e.* *cone-4*-type calixarene with 3'(or 2-*N*-)substituted LacNAc. Further tailoring the nature of the substituent to fully match the galectin's individual microenvironment in the contact site, comprising Arg144, His158, Asn160, Lys176 and Trp181,^{5a,c} affords the possibility for iterative improvements. Using bivalent glycophanes with/without conformational flexibility the attained selectivity increases could then be exploited to affect galectin-3 and its proteolytically processed form differently.¹⁴ 2'-Substitution and starburst glycodendrimers will be worthy of testing VAA,^{7,15} and the sulfate headgroup is a commendable candidate for galectin-4.^{4c,16} In general terms, the presented strategy to amalgamate carbohydrate and supramolecular chemistry can have relevance beyond the particular lectins tested in this study.

We thank the EC GlycoHIT program for generous funding, the Ministero dell'Istruzione, Università e Ricerca (MIUR, PRIN-project no. 200858SA98), the Centro

Interdipartimentale Misura "G. Casnati" for use of NMR facilities, the Conseil Régional de Picardie for a post-doctoral fellowship to FMG and Drs B. Friday and S. Namirha for insightful discussions.

Notes and references

- 1 *The Sugar Code. Fundamentals of glycosciences*, ed. H.-J. Gabius, Wiley-VCH, Weinheim, 2009.
- 2 (a) A. Villalobo, A. Nogales-González and H.-J. Gabius, *Trends Glycosci. Glycotechnol.*, 2006, **18**, 1; (b) R. Schwartz-Albiez, in *The Sugar Code. Fundamentals of glycosciences*, ed. H.-J. Gabius, Wiley-VCH, Weinheim, 2009, pp. 447–468.
- 3 (a) N. Yamazaki, S. Kojima, N. V. Bovin, S. André, S. Gabius and H.-J. Gabius, *Adv. Drug Delivery Rev.*, 2000, **43**, 225; (b) D. A. Fulton and J. F. Stoddart, *Bioconjugate Chem.*, 2001, **12**, 655; (c) Y. M. Chabre and R. Roy, in *The Sugar Code. Fundamentals of glycosciences*, ed. H.-J. Gabius, Wiley-VCH, Weinheim, 2009, pp. 53–70; (d) F. Sansone, L. Baldini, A. Casnati and R. Ungaro, *New J. Chem.*, 2010, **34**, 2715.
- 4 (a) C. P. Sparrow, H. Leffler and S. H. Barondes, *J. Biol. Chem.*, 1987, **262**, 7383; (b) Y. Oda, J. Herrmann, M. A. Gitt, C. W. Turck, A. L. Burlingame, S. H. Barondes and H. Leffler, *J. Biol. Chem.*, 1993, **268**, 5929; (c) J. Hirabayashi, T. Hashidate, Y. Arata, N. Nishi, T. Nakamura, M. Hirashima, T. Urashima, T. Oka, M. Futai, W. E. G. Müller, F. Yagi and K.-I. Kasai, *Biochim. Biophys. Acta, Gen. Subj.*, 2002, **1572**, 232; (d) A. M. Wu, J. H. Wu, M.-S. Tsai, J.-H. Liu, S. André, K. Wasano, H. Kaltner and H.-J. Gabius, *Biochem. J.*, 2002, **367**, 653; (e) A. M. Wu, J. H. Wu, J.-H. Liu, T. Singh, S. André, H. Kaltner and H.-J. Gabius, *Biochimie*, 2004, **86**, 317.
- 5 (a) P. Sörme, P. Arnoux, B. Kahl-Knutsson, H. Leffler, J. M. Rini and U. J. Nilsson, *J. Am. Chem. Soc.*, 2005, **127**, 1737; (b) S. André, D. Giguère, T. K. Dam, C. F. Brewer, H.-J. Gabius and R. Roy, *New J. Chem.*, 2010, **34**, 2229; (c) M. Krzeminski, T. Singh, S. André, M. Lensch, A. M. Wu, A. M. J. J. Bonvin and H.-J. Gabius, *Biochim. Biophys. Acta, Gen. Subj.*, 2011, **1810**, 150.
- 6 (a) S. Fort, H.-S. Kim and O. Hindsgaul, *J. Org. Chem.*, 2006, **71**, 7146; (b) I. Cumpstey, E. Salomonsson, A. Sundin, H. Leffler and U. J. Nilsson, *ChemBioChem*, 2007, **8**, 1389.
- 7 (a) O. E. Galanina, H. Kaltner, L. S. Khraltsova, N. V. Bovin and H.-J. Gabius, *J. Mol. Recognit.*, 1997, **10**, 139; (b) M. Jiménez, S. André, C. Barillari, A. Romero, D. Rognan, H.-J. Gabius and D. Solís, *FEBS Lett.*, 2008, **582**, 2309.
- 8 S. André, F. Sansone, H. Kaltner, A. Casnati, J. Kopitz, H.-J. Gabius and R. Ungaro, *ChemBioChem*, 2008, **9**, 1649.
- 9 F.-M. Gautier, F. Djedaini-Pilard and C. Grandjean, *Carbohydr. Res.*, 2011, **346**, 577.
- 10 (a) D. Gupta, H. Kaltner, X. Dong, H.-J. Gabius and C. F. Brewer, *Glycobiology*, 1996, **6**, 843; (b) T. K. Dam, H.-J. Gabius, S. André, H. Kaltner, M. Lensch and C. F. Brewer, *Biochemistry*, 2005, **44**, 12564.
- 11 (a) H.-J. Gabius, *Crit. Rev. Immunol.*, 2006, **26**, 43; (b) J. Kopitz, M. Bergmann and H.-J. Gabius, *IUBMB Life*, 2010, **62**, 624.
- 12 S. K. Patnaik and P. Stanley, *Methods Enzymol.*, 2006, **416**, 159.
- 13 (a) S. André, H. Sanchez-Ruderisch, H. Nakagawa, M. Buchholz, J. Kopitz, P. Forberich, W. Kemmner, C. Böck, K. Deguchi, K. M. Detjen, B. Wiedenmann, M. von Knebel Doeberitz, T. M. Gress, S.-I. Nishimura, S. Rosewicz and H.-J. Gabius, *FEBS J.*, 2007, **274**, 3233; (b) H. Sanchez-Ruderisch, C. Fischer, K. M. Detjen, M. Welzel, A. Wimmel, J. C. Manning, S. André and H.-J. Gabius, *FEBS J.*, 2010, **277**, 3552.
- 14 R. Leyden, T. Velasco-Torrijos, S. André, S. Gouin, H.-J. Gabius and P. V. Murphy, *J. Org. Chem.*, 2009, **74**, 9010.
- 15 S. André, P. J. C. Ortega, M. A. Perez, R. Roy and H.-J. Gabius, *Glycobiology*, 1999, **9**, 1253.
- 16 D. Delacour, V. Gouyer, J.-P. Zanetta, H. Drobecq, E. Leteurte, G. Grard, O. Moreau-Hannedouche, E. Maes, A. Pons, S. André, A. Le Bivic, H.-J. Gabius, A. Manninen, K. Simons and G. Huet, *J. Cell Biol.*, 2005, **169**, 491.